Zoetis Inc. vs Dr. Reddy's Laboratories Limited: SG&A Expense Trends

Pharma Giants' SG&A Expenses: A Decade of Divergence

__timestampDr. Reddy's Laboratories LimitedZoetis Inc.
Wednesday, January 1, 2014387830000001643000000
Thursday, January 1, 2015425850000001532000000
Friday, January 1, 2016457020000001364000000
Sunday, January 1, 2017463720000001334000000
Monday, January 1, 2018469100000001484000000
Tuesday, January 1, 2019488900000001638000000
Wednesday, January 1, 2020501290000001726000000
Friday, January 1, 2021545590000002001000000
Saturday, January 1, 2022620810000002009000000
Sunday, January 1, 20231059310000002151000000
Monday, January 1, 2024772010000002318000000
Loading chart...

Cracking the code

SG&A Expense Trends: Zoetis Inc. vs Dr. Reddy's Laboratories Limited

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Dr. Reddy's Laboratories Limited and Zoetis Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Dr. Reddy's Laboratories Limited, a major player in the global pharmaceutical market, has seen its SG&A expenses more than double, peaking at approximately 106% growth by 2023. In contrast, Zoetis Inc., a leader in animal health, has maintained a more stable expense pattern, with a modest increase of around 31% over the same period. This divergence highlights the different strategic approaches of these companies, with Dr. Reddy's potentially investing heavily in expansion and Zoetis focusing on steady growth. Notably, data for 2024 is incomplete, indicating a need for further analysis as new information becomes available.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025